JSAM
ZBIO icon

J. Safra Asset Management’s Zenas BioPharma ZBIO Stock Holding History

J. Safra Asset Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.68K Sell
224
-46
-17% -$914 ﹤0.01% 473
2026
Q1 		$5.28K Buy
270
+178
+193% +$4K ﹤0.01% 458
2025
Q4 		$3.34K Buy
+92
New +$3.03K ﹤0.01% 487

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

J. Safra Asset Management's ZBIO Position: Q2 2026 in Review

J. Safra Asset Management reduced its Zenas BioPharma (ZBIO) stake by 17% in Q2 2026, selling an estimated $914 and leaving 224 shares worth $5.68K. The position accounts for ﹤0.01% of the portfolio, ranked #473.

J. Safra Asset Management first reported a position in ZBIO in Q4 2025 and has held it in 3 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • J. Safra Asset Management held 224 shares of Zenas BioPharma worth $5.68K as of Q2 2026.
  • J. Safra Asset Management sold 46 Zenas BioPharma shares in Q2 2026, an estimated $914.
  • Zenas BioPharma made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #473 holding.
  • J. Safra Asset Management first reported a position in Zenas BioPharma in Q4 2025 and has held it in 3 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.